BD (Becton, Dickinson and Company) launched its new HemoSphere Alta™ Advanced Monitoring Platform on April 21, 2025, featuring predictive, artificial intelligence (AI)-based algorithms. This platform is designed to help clinicians proactively address blood pressure instability and optimize blood flow in critical situations.
HemoSphere Alta™ is the first major product launch from BD's Advanced Patient Monitoring business since its acquisition, advancing BD's leadership in smart, connected care technologies. A key innovation is the Cerebral Autoregulation Index (CAI), a parameter indicating the brain's ability to maintain stable blood flow despite blood pressure changes, offering personalized insights.
The platform also includes the Acumen Hypotension Prediction Index (HPI)™ software, which predicts low blood pressure events and has been shown to reduce the depth, duration, and severity of hypotension in studies. The monitor features a larger 15-inch high-resolution touchscreen, split-screen views, and voice/gesture commands to streamline the user experience and maintain sterility.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.